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Background: This report assesses the efficacy and safety of palbociclib plus endocrine therapy (ET) in women with hormone
receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer (ABC) with or without visceral
metastases.
Patients and methods: Pre- and postmenopausal women with disease progression following prior ET (PALOMA-3; N¼ 521)
and postmenopausal women untreated for ABC (PALOMA-2; N¼ 666) were randomized 2 : 1 to ET (fulvestrant or letrozole,
respectively) plus palbociclib or placebo. Progression-free survival (PFS), safety, and patient-reported quality of life (QoL) were
evaluated by prior treatment and visceral involvement.
Results: Visceral metastases incidence was higher in patients with prior resistance to ET (58.3%, PALOMA-3) than in patients naive
to ET in the ABC setting (48.6%, PALOMA-2). In patients with prior resistance to ET and visceral metastases, median PFS (mPFS) was
9.2months with palbociclib plus fulvestrant versus 3.4months with placebo plus fulvestrant [hazard ratio (HR), 0.47; 95%
confidence interval (CI), 0.35–0.61], and objective response rate (ORR) was 28.0% versus 6.7%, respectively. In patients with
nonvisceral metastases, mPFS was 16.6 versus 7.3months, HR 0.53; 95% CI 0.36–0.77. In patients with visceral disease and naive to
ET in the advanced disease setting, mPFS was 19.3months with palbociclib plus letrozole versus 12.9months with placebo plus
letrozole (HR 0.63; 95% CI 0.47–0.85); ORR was 55.1% versus 40.0%; in patients with nonvisceral disease, mPFS was not reached with
palbociclib plus letrozole versus 16.8months with placebo plus letrozole (HR 0.50; 95% CI 0.36–0.70). In patients with prior
resistance to ET with visceral metastases, palbociclib plus fulvestrant significantly delayed deterioration of QoL versus placebo plus
fulvestrant, whereas patient-reported QoL was maintained with palbociclib plus letrozole in patients naive to endocrine-based
therapy for ABC.
Conclusions: Palbociclib plus ET prolonged mPFS in patients with visceral metastases, increased ORRs, and in patients
previously treated for ABC, delayed QoL deterioration, presenting a standard treatment option among patients with visceral
metastases amenable to endocrine-based therapy.
Clinical trial registration: NCT01942135, NCT01740427
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Introduction
Many women with hormone receptor-positive, human epider-
mal growth factor receptor 2-negative (HRþ/HER2) ABC
present with visceral metastases, and their prognosis is generally
worse than those without visceral involvement [1]. Endocrine
therapy (ET) is an effective strategy to manage HRþ/HER2
ABC, and sequential ET is the preferred treatment option for
patients without immediately life-threatening diseases or rapidly
progressing visceral metastases [2–4]. Chemotherapy should be
considered for any symptomatic visceral crisis, but otherwise
treatment guidelines recommend three sequential ET regimens
until no clinical benefit is evident or symptomatic visceral disease
occurs [4], for the purpose of delaying the use of chemotherapy
as long as possible. Despite this, many patients with visceral dis-
ease who are not in visceral crisis receive chemotherapy as early-
line treatment [1, 5], although it may be generally associated with
worse tolerability [6] and poorer QoL compared with ET [7].
Significant progress has been made in understanding the
molecular signaling pathways that account for endocrine resist-
ance, leading to development of various targeted therapies aimed
at preventing or reversing resistance [2]. One such therapy is pal-
bociclib, a first-in-class, selective inhibitor of cyclin-dependent
kinases 4 and 6 (CDK 4/6) [8, 9]. Activation of CDK 4/6 pro-
motes cell proliferation, and preclinical studies demonstrated
that inhibition of CDK4/6 by palbociclib caused cell-cycle arrest
in endocrine-resistant breast cancer cell lines [10]. In addition,
combining palbociclib with ET results in synergistic effects [10].
These findings led to the design of clinical studies in which the
addition of palbociclib to ET resulted in significantly improved
progression-free survival (PFS) in both previously treated
(PALOMA-3) and treatment-naive (PALOMA-1 and -2) women
with HRþ/HER2– ABC [11–14].
When evaluating new therapeutic strategies, it is important to
weigh the risk and benefit for high-risk patients, such as those
with visceral organ metastases. To this end, we carried out pre-
specified analyses in the phase III PALOMA-3 and PALOMA-2
studies and compared the efficacy and safety of palbociclib plus
ET in patients with visceral versus nonvisceral metastases. These
studies enrolled patients with varying degrees of ET responsive-
ness: premenopausal and postmenopausal women with resist-
ance to prior ET in PALOMA-3, and postmenopausal women
still treatment naive for advanced disease in PALOMA-2. Because
the prevalence of visceral involvement is higher in patients who
progressed on prior ET compared with patients naive to ET in the
ABC setting, we first analyzed the PALOMA-3 data and then car-
ried out the same analyses for PALOMA-2.
Methods
Patients and study designs
This analysis includes data from the phase III PALOMA-2 and
PALOMA-3 trials. Patients with symptomatic visceral spread who were
at risk of life-threatening complications were excluded from both studies
[12, 13]. Patients remained on treatment until disease progression, unac-
ceptable toxicity, or consent withdrawal [12, 13]. Detailed descriptions of
study methodology have been described elsewhere [12, 13], and are
highlighted in further detail in supplementary Table S1, available at
Annals of Oncology online.
Both studies were approved by institutional review boards or ethics
committees at participating sites and carried out in accordance with the
International Harmonisation Good Clinical Practice guidelines and pro-
visions of the Declaration of Helsinki.
End points
The primary end point was investigator-assessed PFS. Secondary end
points for efficacy included objective response rate (ORR; defined as con-
firmed complete or partial response) [13], and time to response (TTR;
time to first documented complete or partial response). Other secondary
end points included safety and patient-reported outcomes (PROs).
Assessments
In PALOMA-3, visceral metastases referred to lung, liver, brain, pleural,
and peritoneal involvement; in PALOMA-2, visceral referred to any lung
(including pleura) and/or liver involvement. Lung involvement in
PALOMA-3 is defined as the presence of a measurable lesion in the lung,
whereas in PALOMA-2 lung involvement includes nonmeasurable pleura
and pleural effusion in addition to a measurable lung lesion; therefore,
efficacy data for the lung from only the PALOMA-3 study are reported in
this study. During the treatment phase of both studies, efficacy was
evaluated via tumor assessments carried out every 12 weeks—except in
PALOMA-3, scans were every 8 weeks for the first year—from the date of
randomization until radiographic/clinical documentation of progressive
disease per the Response Evaluation Criteria in Solid Tumors (RECIST)
version 1.1 criteria [13]. Safety was assessed at screening, on day 1 of all
treatment cycles, on day 14/15 of cycles 1 and 2, at the end of treatment/
withdrawal, and post treatment follow-up by evaluating treatment-
emergent adverse events (TEAEs) based on incidence, severity (graded by
National Cancer Institute Common Terminology Criteria for Adverse
Events, version 4.0), and the relationship to study drug. PROs were
assessed using the European Organisation for Research and Treatment of
Cancer (EORTC) quality of life questionnaire (QLQ-C30) in PALOMA-
3 and the Functional Assessment of Cancer Therapy-Breast (FACT-B) in
PALOMA-2.
Data analysis
Data cut-off dates were 23 October 2015 for PALOMA-3 (later than 5
December 2014 cut-off date for interim analysis reported by Turner et al.
[12]) and 26 February 2016 for PALOMA-2. For efficacy, safety, and
PROs, the data were analyzed by baseline metastatic site (visceral and
nonvisceral) and treatment arm. Baseline characteristics and efficacy
results were reported for patients in the intent-to-treat populations.
Median PFS (mPFS) was estimated using the Kaplan–Meier (KM)
method. Hazard ratios (HRs) and their 95% confidence intervals (CIs)
were estimated using Cox proportional hazard model. In this report, the
nominal P values for efficacy are presented without adjusting for multi-
plicity. Odds ratios and their 95% CIs were calculated for confirmed
ORRs. A subpopulation treatment effect pattern plot (STEPP) analysis
[15] was conducted to graph the treatment effect for PFS (HR) across a
continuum of baseline treatment-free intervals (TFIs) of various sub-
groups in PALOMA-2; TFI was defined as the time from the end of (neo)-
adjuvant treatment to disease recurrence. TEAEs were reported in the as-
treated population using descriptive statistics. Time to deterioration in
QoL was analyzed using the KM method and P values were calculated
using a one-sided unstratified log-rank test. Overall changes from base-
line scores were compared using a repeated measures mixed-effects
model with an intercept term, treatment, time, treatment-by-time, and
baseline as covariate.
These studies are still on-going to collect survival data.
Original article Annals of Oncology
670 | Turner et al. Volume 29 | Issue 3 | 2018
Downloaded from https://academic.oup.com/annonc/article-abstract/29/3/669/4802189
by Library Institute of Cancer Research user
on 05 July 2018
Results
Patients
The prevalence of visceral metastases was higher in the 304/521
(58.3%) patients with resistance to prior ET in PALOMA-3 than
in the 324/666 (48.6%) patients in the PALOMA-2 study naive to
ET in the advanced disease setting (Table 1). In PALOMA-3, the
most common site for visceral metastases was the liver, 62.5%
and 76.9% in the palbociclib plus fulvestrant and placebo plus
fulvestrant groups, respectively (Table 1), and 50% and 41% of
patients had lung involvement. In PALOMA-2, liver metastases
were present in 35.0% and 41.8% of patients in the palbociclib-
and placebo-containing treatment arms, respectively. Among
patients with nonvisceral disease, 124/217 (57.1%) in PALOMA-
3 and 151/342 (44.2%) in PALOMA-2 had bone-only disease.
More than 70% of patients in PALOMA-3 with visceral or non-
visceral metastases had received previous chemotherapy for their
primary diagnosis (Table 1). Of those patients, more than 30%
with visceral metastases and 30% with nonvisceral metastases
received previous chemotherapy in the advanced setting.
In PALOMA-2, approximately half of the patients with visceral
or nonvisceral metastases had received chemotherapy previously
(Table 1). The majority of patients in both studies had normal
liver enzymes at baseline (i.e. aspartate aminotransferase [AST],
alanine aminotransferase [ALT], and alkaline phosphatase;
Table 1). Less than 2% of patients in both studies had ALT/
AST>3 times the upper limit of normal.
Efficacy
PALOMA-3. At data cut-off (23 October 2015), mPFS was signif-
icantly longer in patients treated with palbociclib plus fulvestrant
than with placebo plus fulvestrant in the presence of visceral
metastases (9.2 months, 95% CI 7.5–11.1 versus 3.4 months,
1.9–5.1, respectively; HR 0.47; 95% CI 0.35–0.61) and in the
absence of visceral metastases (16.6 months, 13.2–NE versus
7.3 months, 4.8–10.9; HR 0.53; 0.36–0.77) (Figure 1A and B;
Table 2). In patients with liver metastases, mPFS was significantly
longer in the palbociclib plus fulvestrant group versus the placebo
plus fulvestrant group (Table 2). In patients with lung metastases,
mPFS was significantly longer in the palbociclib plus fulvestrant
group versus the placebo plus fulvestrant group (11.1 months,
95% CI 9.3–12.0 versus 3.6 months 2.1–7.2, respectively, HR 0.45
(95% CI 0.29–0.68). In patients with bone-only disease, mPFS was
longer with palbociclib plus fulvestrant compared with placebo
plus fulvestrant (14.3 months, 95% CI 11.2–NE versus 9.2 months,
4.8–20.0, respectively; HR 0.63; 95% CI 0.38–1.06) (Figure 1C).
The ORR was significantly higher in patients with visceral
metastases treated with palbociclib plus fulvestrant versus pla-
cebo plus fulvestrant (28.0% versus 6.7%, respectively, Table 2).
ORRs were significantly higher in patients with liver metastases
(27.2% versus 3.8%) (Table 2) and numerically higher in patients
with lung metastases (25.0% versus 11.6%) in the palbociclib
plus fulvestrant group compared with the placebo plus fulves-
trant group. For patients with liver metastases, median TTR
(mTTR) was also shorter with palbociclib plus fulvestrant treat-
ment than with placebo plus fulvestrant (3.8 versus 5.6 months)
(Table 2) and the mTTR in lung tumoral lesions was 3.9 and
3.6 months, respectively.
PALOMA-2. At data cut-off (26 February 2016), mPFS for
patients with visceral metastases was significantly longer in
those treated with palbociclib plus letrozole compared with pla-
cebo plus letrozole (19.3 months, 95% CI 16.4–22.2 versus
12.9 months, 8.4–16.6, respectively; HR 0.63; 95% CI 0.47–0.85)
(Figure 1D). In patients without visceral metastases, mPFS was
also significantly longer in patients treated with palbociclib plus
letrozole versus those treated with placebo plus letrozole with the
mPFS not yet reached for patients in the palbociclib plus letrozole
group (Figure 1E). In patients with liver metastases, mPFS was
significantly longer in patients treated with palbociclib plus letro-
zole compared with placebo plus letrozole (13.7 months, 95% CI
10.9–16.6 versus 8.4 months, 5.5–12.9, respectively; HR 0.62;
95% CI 0.41–0.95). For patients with bone-only disease, mPFS
was significantly prolonged with palbociclib plus letrozole com-
pared with placebo plus letrozole (not reached, 95% CI 24.8–NE
versus 11.2 months, 8.2–22.0, respectively; HR 0.36; 95% CI
0.22–0.59) (Figure 1F).
The ORR was significantly higher in patients with visceral
metastases treated with palbociclib plus letrozole compared with
placebo plus letrozole (55.1% versus 40.0%, respectively;
Table 2). The ORR and mTTR were similar between palbociclib
plus letrozole and placebo plus letrozole treatment groups in
patients with liver metastases (ORR: 41.3% versus 37.0%, respec-
tively; mTTR: 3.0 and 2.9 months; Table 2).
The exploratory STEPP analysis carried out on PALOMA-2
baseline TFI data revealed that the treatment effect on PFS (in
terms of HR) remained relatively constant across study subpopu-
lations regardless of the length of baseline TFI (Figure 2).
Patient-reported outcomes
In PALOMA-3, a statistically significantly greater delay in time to
deterioration in global QoL was observed in the subgroup with
visceral metastases, who were treated with palbociclib plus fulves-
trant compared with placebo plus fulvestrant (HR 0.54;
P< 0.001; Figure 3A). A similar trend was observed between
treatments in patients without visceral metastases but it was not
statistically significant (Figure 3B). In patients with visceral meta-
stases, the overall change in QLQ-C30 scales from baseline scores
favored the palbociclib plus fulvestrant group for global health/
QoL, emotional functioning, role functioning (supplementary
Figure S1, available at Annals of Oncology online) and symptoms
like pain, nausea and vomiting, and insomnia (all P< 0.05). No
significant differences were observed between treatment arms in
the nonvisceral metastases group. In PALOMA-2, patient-
reported QoL, as assessed by the FACT-B total score, was main-
tained with the addition of palbociclib to letrozole; no significant
differences were observed between treatment groups in the vis-
ceral and nonvisceral metastases subgroups (Figure 3C and D).
No significant difference in time to deterioration in QoL was
observed between treatment arms in the patients with and with-
out visceral metastases.
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Table 1. Demographic and baseline characteristics by treatment group for patients with and without visceral metastases
Characteristics PALOMA-3a,b PALOMA-2a,b
PAL1FUL PBO1FUL PAL1LET PBO1LET
Visceral Nonvisceral Visceral Nonvisceral Visceral Nonvisceral Visceral Nonvisceral
(n5 200) (n5 147) (n5 104) (n570) (n5 214) (n5230) (n5 110) (n5 112)
Median (range) age, years 57.0 57.0 58.5 54.0 62.0 62.0 61.0 62.0
(30.0–88.0) (33.0–82.0) (35.0–80.0) (29.0–74.0) (30.0–88.0) (36.0–89.0) (28.0–88.0) (32.0–88.0)
Involved disease sitesc
Liver 125 (62.5) – 80 (76.9) – 75 (35.0) – 46 (41.8) –
Lymph node 97 (48.5) 41 (27.9) 39 (37.5) 24 (34.3) 125 (58.4) 87 (37.8) 65 (59.1) 45 (40.2)
Bone 136 (68.0) 128 (87.1) 76 (73.1) 54 (77.1) 126 (58.9) 199 (86.5) 73 (66.4) 89 (79.5)
Peritoneum 1 (<1) – 0 – 4 (1.9) – 0 –
Number of metastatic organ sitesc
1 17 (8.5) 94 (63.9) 11 (10.6) 49 (70.0) 17 (7.9) 121 (52.6) 6 (5.5) 60 (53.6)
2 63 (31.5) 32 (21.8) 37 (35.6) 14 (20.0) 63 (29.4) 54 (23.5) 26 (23.6) 26 (23.2)
3 58 (29.0) 15 (10.2) 27 (26.0) 6 (8.6) 66 (30.8) 46 (20.0) 41 (37.3) 20 (17.9)
4 43 (21.5) 3 (2.0) 20 (19.2) 0 45 (21.0) 7 (3.0) 23 (20.9) 6 (5.4)
>4 18 (9.0) 2 (1.4) 9 (8.7) 0 23 (10.7) 2 (<1.0) 14 (12.7) 0
ECOG performance status
0 114 (57.0) 92 (62.6) 66 (63.5) 50 (71.4) 113 (52.8) 144 (62.6) 51 (46.4) 51 (45.5)
1 86 (43.0) 55 (37.4) 38 (36.5) 20 (28.6) 97 (45.3) 81 (35.2) 59 (53.6) 58 (51.8)
2 – – – – 4 (1.9) 5 (2.2) 0 3 (2.7)
Prior endocrine therapyd
Tamoxifen only 4 (2.0) 1 (<1.0) 3 (2.9) 1 (1.4) 72 (33.6) 59 (25.7) 40 (36.4) 33 (29.5)
Aromatase inhibitor 23 (11.5) 21 (14.3) 9 (8.7) 7 (10.0) 14 (6.5) 19 (8.3) 8 (7.3) 20 (17.9)
Both tamoxifen and aromatase inhibitor 96 (48.0) 63 (42.9) 50 (48.1) 31 (44.3) 38 (17.8) 40 (17.4) 15 (13.6) 10 (8.9)
Prior chemotherapye 149 (74.5) 103 (70.1) 81 (77.9) 56 (80.0) 106 (49.5) 107 (46.5) 60 (54.5) 49 (43.8)
Neoadjuvant 40 (20.0) 26 (17.7) 20 (19.2) 13 (18.6) 33 (15.4) 21 (9.1) 15 (13.6) 17 (15.2)
Adjuvant 85 (42.5) 66 (44.9) 47 (45.2) 41 (58.6) 88 (41.1) 92 (40.0) 51 (46.4) 38 (33.9)
Advanced/metastatic setting 68 (34.0) 39 (26.5) 41 (39.4) 21 (30.0) – – – –
Liver function tests
AST
ULN 143 (71.5) 124 (84.4) 69 (66.3) 60 (85.7) 171 (79.9) 197 (85.7) 92 (83.6) 103 (92.0)
>1 and 2 ULN 47 (23.5) 20 (13.6) 24 (23.1) 4 (5.7) 35 (16.4) 31 (13.5) 15 (13.6) 9 (8.0)
>2 and 3 ULN 6 (3.0) 3 (2.0) 5 (4.8) 2 (2.9) 6 (2.8) 2 (0.9) 3 (2.7) 0
>3 ULN 4 (2.0) 0 4 (3.8) 0 2 (0.9) 0 0 0
ALT
ULN 170 (85.0) 131 (89.1) 79 (76.0) 63 (90.0) 180 (84.1) 202 (87.8) 97 (88.2) 103 (92.0)
>1 and 2 ULN 21 (10.5) 14 (9.5) 20 (19.2) 2 (2.9) 33 (15.4) 27 (11.7) 12 (10.9) 6 (5.4)
>2 and 3 ULN 7 (3.5) 1 (0.7) 3 (2.9) 3 (4.3) 1 (0.5) 1 (0.4) 1 (0.9) 2 (1.8)
>3 ULN 2 (1.0) 0 2 (1.9) 0 0 0 0 1 (0.9)
Alkaline phosphatase
ULN 152 (76.0) 124 (84.4) 77 (74.0) 58 (82.9) 165 (77.1) 174 (75.7) 86 (78.2) 92 (82.1)
>1 and 2 ULN 35 (17.5) 19 (12.9) 21 (20.2) 6 (8.6) 37 (17.3) 47 (20.4) 22 (20.0) 18 (16.1)
>2 and 3 ULN 9 (4.5) 1 (0.7) 4 (3.8) 2 (2.9) 7 (3.3) 5 (2.2) 2 (1.8) 0
>3 ULN 2 (1.0) 3 (2.0) 2 (1.9) 0 5 (2.3) 4 (1.7) 0 2 (1.8)
aValues are n (%) unless stated otherwise.
bPatients with visceral metastases were deﬁned as those reported in the case report forms by the Principle Investigators, not those reported in the
IMPALA randomization system. Involved sites include both target and nontarget sites; sites with multiple lesions are counted once.
cPatients in PALOMA-2 were treatment-naive for advanced breast cancer.
dData represent prior endocrine therapy for primary diagnosis.
eData represent previous chemotherapy regimen for primary diagnosis.
–, no data; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ECOG, Eastern Cooperative Oncology Group; FUL, fulvestrant; LET, letrozole;
PAL, palbociclib; PBO, placebo; ULN, upper limit of normal.
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Figure 1. Kaplan–Meier plots of progression-free survival in patients in the PALOMA-3 study with visceral metastases (A), nonvisceral meta-
stases (B), and bone-only disease (C), as well as in patients in the PALOMA-2 study with visceral metastases (D), nonvisceral metastases (E),
and bone-only disease (F). HR, hazard ratio; NE, not estimable; NR, not reached.
Annals of Oncology Original article
Volume 29 | Issue 3 | 2018 doi:10.1093/annonc/mdx797 | 673
Downloaded from https://academic.oup.com/annonc/article-abstract/29/3/669/4802189
by Library Institute of Cancer Research user
on 05 July 2018
DE
Time, months
Pr
og
re
ss
io
n-
fre
e 
su
rv
iv
al
, %
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
Number at risk:
0
20
40
60
80
100
230
112
223
109
223
106
210
92
208
92
207
91
193
80
193
79
191
79
178
73
177
73
173
69
160
65
159
65
153
58
148
57
147
56
138
48
137
46
135
46
95
32
92
31
86
28
47
15
46
13
26
11
19
8
19
8
7
3
6
3
6
3
3
2
3
2
2
2
0
0
24 25 26 27 28 29 30 31 32 33 34
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34
Palbociclib + Letrozole, median NR months (95% CI, 25.1–NE)
Placebo + Letrozole, median 16.8 months (95% CI, 13.7–22.2)
Censored
HR, 0.50 (95% CI, 0.36–0.70), P < 0.0001
F
Time, months
Pr
og
re
ss
io
n-
fre
e 
su
rv
iv
al
, %
Number at risk:
0
20
40
60
80
100
Palbociclib + Letrozole, median NR months (95% CI, 24.8–NE)
Placebo + Letrozole, median 11.2 months (95% CI, 8.2–22.0)
Censored
HR, 0.36 (95% CI, 0.22–0.59), P < 0.0001
103
48
100
46
100
44
91
35
91
35
91
35
87
31
87
31
86
31
83
27
83
27
82
24
78
21
77
21
76
21 21
74
21
74
16
67
16
67
16
65
11
46
11
46
9
44
3
26
3
25
2
13
1
11
1
3 33
0
211 2 1 0
Time, months
Pr
og
re
ss
io
n-
fre
e 
su
rv
iv
al
, %
Number at risk:
0
20
40
60
80
100
214
110
207
103
202
98
185
79
184
78
182
75
167
68
165
67
163
66
150
58
149
57
144
54
135
51
131
47
116
43
115
41
114
41
101
37
101
35
101
33
64
24
62
23
53
20
24
10
23
9
13
4
10
4
10
4
4
1
4
1
4
1
0
1 0
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34
Palbociclib + Letrozole, median 19.3 months (95% CI, 16.4–22.2)
Placebo + Letrozole, median 12.9 months (95% CI, 8.4–16.6)
Censored
HR, 0.63 (95% CI, 0.47–0.85), P < 0.01
Figure 1. Continued.
Original article Annals of Oncology
674 | Turner et al. Volume 29 | Issue 3 | 2018
Downloaded from https://academic.oup.com/annonc/article-abstract/29/3/669/4802189
by Library Institute of Cancer Research user
on 05 July 2018
Safety
In both PALOMA studies, most patients experienced1 TEAE
regardless of visceral metastatic status and treatment group (sup-
plementary Table S2, available at Annals of Oncology online), and
the rates of TEAEs leading to palbociclib or placebo permanent
discontinuation were similarly low between patients with and
without visceral metastases (PALOMA-3, all patients6.2%;
PALOMA-2, all7%, except 11.3% in nonvisceral patients
receiving palbociclib plus letrozole). For palbociclib plus ET, the
rate of grade 3 TEAEs>5%, as well as the rates of TEAEs leading
to temporary treatment discontinuations or dose reductions in
PALOMA-3 and -2 were comparable across groups, despite the
presence or absence of visceral metastases (supplementary Tables
S2 and S3, available at Annals of Oncology online). Permanent dis-
continuations due to AEs among all subgroups of patients were
low, particularly in relation to reports of neutropenia and regard-
less of the presence or absence of visceral disease. Among patients
with visceral metastases, the most commonly reported grade 3
TEAEs of>5% incidence were neutropenia (54.8%) and leuko-
penia (43.2%) in patients treated with palbociclib plus fulvestrant
in PALOMA-3 and neutropenia (57.5%) and leukopenia
(22.4%) in patients treated with palbociclib plus letrozole in
PALOMA-2 (supplementary Table S3, available at Annals of
Oncology online). The incidence of infections of any grade was
similar between visceral and nonvisceral palbociclib-treated
patients across both studies in PALOMA-3 (42.2% and 46.6%,
respectively) and PALOMA-2 (56.1% and 63.0%) (supplemen-
tary Table S3, available at Annals of Oncology online). Infections
of any grade in patients who received placebo plus fulvestrant
were lower in patients with visceral metastases (28.8%) due to the
very short duration of treatment than with nonvisceral metasta-
ses (35.3%), and similar to the pattern reported in patients who
received placebo plus letrozole (38.2% and 46.4%, respectively)
(supplementary Table S3, available at Annals of Oncology online).
Within PALOMA-3 and -2, grade 3 and 4 AEs of>5% incidence
were similar between patients receiving palbociclib and ET.
Serious AEs of>1% incidence for any grade and grades 3 and 4
Table 2. Median PFS, ORR, and TTR by treatment group for patients with and without visceral metastases
PALOMA-3 PALOMA-2
(N5521) (N5666)
Visceral Nonvisceral Visceral Nonvisceral
PAL1FUL
versus
PBO1FUL
PAL1FUL
versus
PBO1FUL
PAL1LET
versus
PBO1LET
PAL1LET
versus
PBO1LET
ITT population, n 200 versus 104 147 versus 70 214 versus 110 230 versus 112
mPFS, months 9.2 versus 3.4 16.6 versus 7.3 19.3 versus 12.9 NR versus 16.8
HR (95% CI) 0.47 (0.35–0.61) 0.53 (0.36–0.77) 0.63 (0.47–0.85) 0.50 (0.36–0.70)
ORR, % 28.0 versus 6.7 11.6 versus 11.4 55.1 versus 40.0 30.0 versus 29.5
OR (95% CI) 5.39 (2.31–14.55) 1.01 (0.39–2.87) 1.84 (1.13–3.03) 1.03 (0.61–1.74)
mTTR, months 3.8 and 3.6 3.7 and 3.6 4.3 and 5.3 2.9 and 5.4
Patients with liver metastases, n 125 versus 80 – 75 versus 46 –
mPFS, months 7.5 versus 2.4 – 13.7 versus 8.4 –
HR (95% CI) 0.49 (0.36–0.68) – 0.62 (0.41–0.95) –
ORR, % 27.2 versus 3.8 – 41.3 versus 37.0 –
mTTR, months 3.8 and 5.6 – 3.0 and 2.9 –
Patients without visceral metastases
and excluding bone-only, n
61 versus 32 128 versus 64
mPFS, months – 16.6 versus 5.6 – 27.6 versus 21.9
HR (95% CI) – 0.43 (0.24–0.76) – 0.65 (0.42–1.03)
Patients with visceral metastases and
ECOG performance status 0, n
114 versus 66 – 113 versus 51 –
mPFS, months 9.4 versus 3.6 – 19.4 versus 16.4 –
HR (95% CI) 0.52 (0.37–0.74) – 0.89 (0.56–1.40) –
ORR, % 32.5 versus 10.6 – 54.0 versus 47.1 –
Patients with visceral metastases and
ECOG performance status 1 or 2, n
86 versus 38 – 101 versus 59 –
mPFS, months 9.2 versus 2.0 – 16.8 versus 11.0 –
HR (95% CI) 0.37 (0.24–0.57) – 0.48 (0.32–0.71) –
ORR, % 22.1 versus 0 – 56.4 versus 33.9 –
CI, conﬁdence interval; ECOG, Eastern Cooperative Oncology Group; FUL, fulvestrant; HR, hazard ratio; ITT, intent-to-treat; LET, letrozole; m, median; NR, not reached,
not estimable; OR, odds ratio; ORR, overall response rate; PAL, palbociclib; PBO, placebo; PFS, progression-free survival; TTR, time to response.
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(palbociclib- or placebo-related) were low in patients receiving
palbociclib and ET regardless of visceral metastases, and similarly
low between patients treated with placebo plus ET, regardless of
visceral metastases (supplementary Table S3, available at Annals
of Oncology online).
Discussion
Patients with HRþ/HER2– ABC with visceral metastases repre-
sent a clinical challenge as their prognosis is generally worse than
that of patients without visceral involvement [1]. In this
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Figure 2. STEPP analysis results of the PFS treatment effect and baseline TFI in subpopulations of patients in the PALOMA-2 study who
received adjuvant therapy (A), patients who received adjuvant therapy and had visceral metastases (B), and patients who received adjuvant
therapy and had nonvisceral metastases (C). TFI, treatment-free interval (for the purposes of this study, TFI was considered equivalent to dis-
ease-free interval [prespeciﬁed] in the PALOMA-2 study and was deﬁned as the time from the end of [neo]adjuvant treatment to disease
recurrence); PFS, progression-free survival; STEPP, subpopulation treatment effect pattern plot.
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subgroup analysis of patients from PALOMA-3 and PALOMA-2,
mPFS was significantly prolonged in patients with and without
visceral metastases at baseline when they were treated with palbo-
ciclib plus fulvestrant or letrozole compared with placebo plus
fulvestrant or letrozole. These results are consistent with the
smaller randomized phase II PALOMA-1 study [16]. The per-
centage of patients with visceral metastases was higher in
PALOMA-3 than in PALOMA-2, which is consistent with evi-
dence from clinical practice in which patients receiving later lines
of therapy and/or with prior endocrine resistance were more
likely to have visceral metastases compared with patients with de
novo metastatic disease.
In the PALOMA-2 study, a STEPP analysis did not identify
an interaction between the PFS treatment effect and baseline
TFI in patients who had received adjuvant therapy and in
subgroups based on visceral or nonvisceral metastases. This is
in contrast to the results from the double-blind, randomized,
phase III MONARCH 3 study, which compared the addition of
abemaciclib or placebo with a nonsteroidal aromatase inhibitor
to evaluate investigator-assessed PFS, the primary study end
point, in postmenopausal women with HRþ/HER2ABC
[17]. In the overall population in MONARCH 3, PFS HRs were
lower in subpopulations with a baseline TFI<36 months (an
adverse prognostic factor) and increased in subpopulations
with TFIs>36 months (a more favorable prognostic factor)
[18]. In MONARCH 3, TFI, defined as the time from the end of
adjuvant ET until informed consent [17], is similar to the defi-
nition for TFI in our analysis of PALOMA-2. However, the
median follow-up duration was shorter in the MONARCH 3
study than in PALOMA-2, with few progression events in
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patients with TFI36 months [13, 17]; the difference in find-
ings between the studies is potentially explained by the different
durations of follow-up.
In the PALOMA-3 and PALOMA-2 studies, the improvement
in PFS with palbociclib plus ET was consistent in patients with
bone-only disease at baseline versus placebo plus ET, with sub-
stantial absolute benefit from the addition of palbociclib most
evident in PALOMA-2 (Figure 1). The addition of abemaciclib to
ET also likely provided PFS benefit over endocrine monotherapy
in patients with bone-only disease at baseline in the MONARCH
3 study (HR 0.58, 95% CI 0.27–1.25) [17], although the statistical
analysis of this result may be affected by the shorter duration of
follow-up time.
In the phase III, randomized, double-blind, MONARCH 2
study, 373 out of the 669 (55.8%) women of any menopausal sta-
tus with HRþ/HER2 ABC who had progressed on (neo)adju-
vant ET within 12 months from the end of adjuvant ET, or while
receiving front-line treatment of metastatic disease, had visceral
disease at baseline [19]. The patients in this study were treated
with either abemaciclib (150 mg twice daily, on a continuous
schedule) plus fulvestrant (500 mg) or placebo plus fulvestrant.
Although the patient population in MONARCH 2 had not
received prior chemotherapy and were less heavily pretreated
than patients in PALOMA-3, investigator-assessed PFS (primary
end point) in patients with visceral disease was significantly more
favorable following treatment with abemaciclib plus fulvestrant
than with ET alone (HR 0.481; 95% CI 0.369–0.627), demon-
strating the favorable effect of CDK 4/6 inhibitors across a spec-
trum of patients [19]. The time to deterioration in global QoL
was significantly delayed in patients with visceral metastases who
were treated with palbociclib plus fulvestrant compared with the
placebo arm.
Chemotherapy is often used in patients with visceral metasta-
ses who are not in visceral crisis, despite worse clinical outcomes
[20]. A network meta-analysis comparing palbociclib treatment
with chemotherapy agents for the treatment of HRþ/
HER2ABC showed that palbociclib plus fulvestrant and palbo-
ciclib plus letrozole demonstrate a trend in incremental efficacy
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compared with chemotherapy agents for the first-line and previ-
ously treated patients [21]. However, a head-to-head comparison
between ET combined with a CDK4/6 inhibitor versus chemo-
therapy is currently lacking and as such the results of the network
meta-analysis reported by Wilson et al. should be interpreted
with caution [21]. Our findings highlight the benefit of
palbociclib-containing combination therapy for patients with
visceral metastases without the cytotoxic effects of chemotherapy.
Furthermore, no new safety findings were observed relative to the
AE profiles reported in the primary PALOMA-3 and PALOMA-2
studies [12, 13]. Of importance is the analysis of patients with
liver metastases. Our studies do not suggest that liver metastases
should be treated differently, despite the fact that overall out-
comes for such patients may be inferior with respect to the whole
study population.
Comparisons with other studies should be interpreted with
caution. In the recent phase III FALCON study in endocrine-
naive patients with HRþABC, patients with visceral metastases
treated with fulvestrant had a mPFS that was similar to patients
treated with anastrozole (13.8 versus 15.9 months, respectively)
[22]. A strategy to improve clinical outcomes in endocrine-naive
patients is related to the introduction of targeted therapies, as was
evident in PALOMA-2, in which mPFS was significantly pro-
longed with palbociclib plus letrozole in patients with visceral
metastases versus placebo plus letrozole treatment (19.3 versus
12.9 months, respectively). In patients with nonvisceral disease in
the FALCON study, mPFS was significantly longer in patients
treated with fulvestrant (22.3 months) compared with anastro-
zole (13.8 months); however, the number of patients with locally
advanced stage IIIb or IIIc disease included in that study was not
reported [22]. In PALOMA-2, the mPFS of palbociclib plus letro-
zole has not yet been reached in patients without visceral metasta-
ses after a median follow-up of 23 months.
Although the comparisons between patients with and without
visceral metastases were prespecified analyses in PALOMA-3 and
PALOMA-2, patients with advanced visceral metastases (i.e.
patients with symptomatic visceral spread who were at risk of
life-threatening complications) were excluded from both studies
[12, 13]. Therefore, our findings should not be extrapolated to
this subpopulation. Guidelines limit the use of ET to patients
without life-threatening visceral metastases; however, our find-
ings lend further support to recommendations for use of ET for
the management of HRþ/HER2– ABC as initial or salvage ther-
apy, even in the presence of visceral metastases [2–4].
Conclusions
The findings of this prespecified subgroup analysis demonstrate
the clinical benefit of palbociclib in combination with ET in
patients with HRþ/HER2– ABC with visceral metastases.
Median PFS and response rate compare favorably with that seen
with chemotherapy. The deterioration in symptoms for global
QoL assessment were delayed in patients with prior resistance to
ET and visceral disease and maintained by the addition of palbo-
ciclib to ET in patients with visceral disease who were previously
untreated with systemic ET for ABC.
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